COLORADO SPRINGS, Colo., May 9 /PRNewswire-FirstCall/ -- Spectranetics Corporation announced today it has appointed Larry O. Adighije as Vice President, Business Development and Strategy, reporting directly to the Company’s Chief Operating Officer, Will McGuire.
Mr. Adighije was previously senior director of business development and strategic marketing for Edwards Lifesciences, where he led development operations for the firm’s vascular division. While at Edwards, he was instrumental in the acquisition, development and introduction of the LifeStent self-expanding stent. Prior to that, he was senior global group marketing manager for Medtronic Interventional Vascular, and senior global product manager with the Vascular Therapies division of U.S. Surgical. Mr. Adighije has a Bachelor of Science degree in Accounting from Kansas State University, and a Master of Business Administration degree from Jacksonville State University.
“Larry Adighije’s impressive industry record includes successful product introductions and the building of new businesses, and he will be called upon to leverage that experience at Spectranetics,” said McGuire. “Our recent growth and success, combined with our financial resources, gives us the foundation to grow our business in a number of new directions, and Larry will play a key role in helping us exploit those opportunities.”
About Spectranetics
Founded in 1984, Spectranetics manufactures and sells the only excimer laser approved in the United States, Europe and Japan for use in minimally invasive cardiovascular procedures. This technology treats complex cardiovascular conditions by photo-ablating multiple lesion types into tiny particles that are easily absorbed into the blood stream. The Company’s disposable catheters use high-energy “cool” ultraviolet light to vaporize arterial blockages in the legs and heart, as well as scar tissue encapsulating pacing and defibrillation leads. For more information visit www.spectranetics.com.
Safe Harbor Statement
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties may include increasing price and product competition, increased pressure on expense levels resulting from expanded marketing and clinical activities, uncertain success of the Company’s strategic direction, dependence on new product development, intellectual property claims of third parties, availability of inventory from suppliers, the receipt of FDA approval to market new products or applications and the timeliness of any approvals, the potential size of market opportunities associated with new products, market acceptance of new products or applications, product defects, price volatility due to the initiation or cessation of coverage, or changes in ratings, by securities analysts. For a further list and description of such risks and uncertainties that could cause the actual results, performance or achievements of the Company to be materially different from any anticipated results, performance or achievements, please see the Company’s previously filed SEC reports. Spectranetics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events or otherwise.
COMPANY CONTACT: INVESTOR & MEDIA CONTACTS: Spectranetics Corporation Lippert/Heilshorn & Associates, Inc. Guy Childs, Chief Financial Officer Bruce Voss (719) 633-8333 Don Markley (310) 691-7100 www.spectranetics.comwww.lhai.com
Spectranetics Corporation
CONTACT: Guy Childs, Chief Financial Officer of Spectranetics Corporation,+1-719-633-8333; or Investors and Media, Bruce Voss and Don Markley, bothof Lippert/Heilshorn & Associates, Inc., +1-310-691-7100, for SpectraneticsCorporation
Web site: http://www.spectranetics.com/
